MRNA EPS
Net income divided by diluted shares outstanding — the per-share profit earned each quarter.
EPS
Latest: −$1.97 (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | $0.19 |
| 2023Q2 | −$3.62 |
| 2023Q3 | −$9.53 |
| 2023Q4 | $0.56 |
| 2024Q1 | −$3.07 |
| 2024Q2 | −$3.33 |
| 2024Q3 | $0.03 |
| 2024Q4 | −$2.91 |
| 2025Q1 | −$2.52 |
| 2025Q2 | −$2.13 |
| 2025Q3 | −$0.51 |
| 2025Q4 | −$2.11 |
| 2026Q1 | −$3.40 |
| 2026Q2 | −$1.97 |
Other MRNA Charts
More quarter-by-quarter fundamentals for Moderna, Inc.
1 / 10
Revenue
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Latest EPS: −$1.97 (2026Q2); +7.5% YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, EPS ranged from −$9.53 in 2023Q3 to $0.56 in 2023Q4.